Compare NAT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAT | AKBA |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.8M | 729.1M |
| IPO Year | 1997 | 2014 |
| Metric | NAT | AKBA |
|---|---|---|
| Price | $3.91 | $1.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.25 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 2.9M | 2.7M |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 8.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $294,820,000.00 | $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | $25.84 | $22.45 |
| P/E Ratio | $434.39 | ★ N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $2.13 | $1.45 |
| 52 Week High | $3.93 | $4.08 |
| Indicator | NAT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 70.83 | 39.71 |
| Support Level | $3.36 | $1.46 |
| Resistance Level | $3.51 | $1.57 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 96.69 | 20.37 |
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.